This inventor holds 1 USPTO granted patent and 10 published patent applications. Top assignee: Regenxbio Inc.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Curran Matthew Simpson: Innovator in Mucopolysaccharidosis Treatment
Introduction
Curran Matthew Simpson is a notable inventor based in Frederick, MD (US). He has made significant contributions to the field of medicine, particularly in the treatment of rare genetic disorders. His innovative work focuses on developing therapies that can improve the quality of life for patients suffering from mucopolysaccharidosis II.
Latest Patents
Curran Matthew Simpson holds a patent for the "Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cells." This patent describes compositions and methods for delivering recombinant human iduronate-2-sulfatase (IDS) to the cerebrospinal fluid of the central nervous system (CNS) in individuals diagnosed with mucopolysaccharidosis II. This groundbreaking work has the potential to transform treatment options for patients affected by this condition.
Career Highlights
Curran Matthew Simpson is currently associated with Regenxbio Inc., a company dedicated to advancing gene therapy solutions. His role at the company allows him to leverage his expertise in developing innovative treatments that address unmet medical needs. With a focus on research and development, he continues to push the boundaries of what is possible in the field of genetic disorders.
Collaborations
Throughout his career, Curran has collaborated with esteemed colleagues, including Stephen Yoo and Rickey Robert Reinhardt. These partnerships have fostered an environment of innovation and have contributed to the advancement of therapeutic strategies in the medical field.
Conclusion
Curran Matthew Simpson's work exemplifies the spirit of innovation in the treatment of mucopolysaccharidosis II. His contributions through patents and collaborations highlight the importance of research in developing effective therapies for rare diseases. His ongoing efforts at Regenxbio Inc. continue to inspire advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile